Rotigotine safety in real-world settings: a pharmacovigilance study using FAERS data

Area of Science:

• Pharmacovigilance and Drug Safety
• Neurology and Movement Disorders
• Pharmaceutical Sciences

Background:

• Assessing adverse reactions to rotigotine using spontaneous reports from the FDA Adverse Event Reporting System (FAERS).
• Providing crucial insights for optimizing clinical dosing strategies for rotigotine therapy.

Purpose of the Study:

• To evaluate the safety profile of rotigotine by analyzing spontaneous adverse event reports.
• To identify and characterize adverse events (AEs) associated with rotigotine use.

Main Methods:

• Retrospective analysis of FAERS data from Q2 2007 to Q2 2024.
• Utilized four disproportionality analysis methods: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multinomial Gamma Poisson Shrinkage (MGPS).

Main Results:

• Analysis of 7,570 rotigotine-related AE reports from over 17.5 million FAERS reports.
• Identified 172 preferred terms (PTs) with significant disproportionality, including product adhesion issue (predominant AE), drug ineffectiveness, fall incidents, and Parkinson's disease.
• Median time to AE onset was 213 days, with events occurring within 30 days and after 360 days of therapy.

Conclusions:

• Findings align with the known safety profile of rotigotine.
• Revealed unexpected serious adverse events, underscoring the need for ongoing monitoring.
• Emphasizes the importance of continued vigilance in post-marketing surveillance for rotigotine.